Biomarker Discovery Firm Biospect Raises $27M in Financing, Appoints CEO | GenomeWeb

NEW YORK, Oct. 21 (GenomeWeb News) - Biospect, a South San Francisco, Calif.-based startup developing systems for detecting biomarker patterns, today said it has received more than $27 million in equity financing from four venture capital firms: Advent Venture Partners, Prospect Venture Partners, Venrock Associates, and Versant Ventures. 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nucleic Acids Research this week: nanopore sequencing workflow to detect antibiotic resistance in gut microbes, TSSPlant tool, and more.

Because gene-edited organisms can cross borders, Gizmodo wonders whether there should be an international body to govern their use.

HHS Secretary nominee Tom Price is to go in front of the Senate Committee on Health, Education, Labor and Pensions today, NPR's Morning Edition reports.

Prior to being closed, Theranos' Arizona lab failed an inspection by regulators, according to the Wall Street Journal.